The engineering world is focusing on “Sovereign Capability” at the NEC this week. However, the UK Life Sciences sector has just provided a masterclass in making it a reality.
A fresh £80m investment has been unlocked by the government’s Life Sciences Innovative Manufacturing Fund (LSIMF). However, the UK is solidifying its position as a global powerhouse for medicine production. This latest surge brings the total investment in the sector to £600 million this year alone. Importantly, this supports more than 500 highly skilled jobs across regional clusters from Birmingham to Barnstaple.
The ‘Near-Patient’ Revolution: Speeding Up the Cure
The standout storycomes from the University of Birmingham. Specifcally, their Precision Health Technologies Accelerator (PHTA) is investing £10m to establish a new near-patient biomanufacturing facility.
The Mission: To slash the time it takes to get personalised treatments to patients.
The Breakthrough: Birmingham is already leading Europe’s first trial of a personalised mRNA vaccine for pancreatic cancer. But, by building “clean rooms” directly next to the patient, the “tumour-to-vaccine” journey becomes faster than ever. Even allowing the immune system to fight back before cancer can recur.
Barnstaple’s £45m Strategic Anchor
In North Devon, Accord Healthcare, which supplies a staggering 9% of all NHS prescriptions, is injecting £45 million into its Barnstaple site. This isn’t just about generic medicine; the site will now produce novel treatments for conditions like bipolar disorder.
James Selka’s calls at MACH for “Sovereign Capability” are echoed here: by manufacturing more in the UK, we secure our own supply chains against global shocks.
UK Life Sciences Next-Gen Tech: The PSD 4
In Haverhill, Codis is installing the UK’s only commercial-scale, solvent-capable GEA PSD 4 spray dryer. This advanced technology improves the “bioavailability” of difficult-to-manufacture medicines, making next-generation therapies for cancer and neurodegenerative diseases more accessible to the masses.
Strategic Growth: The £1 Billion Goal
Science and Technology Secretary Liz Kendall highlighted that the UK’s Life Sciences Sector Plan is on track to unlock £1 billion in investment by the summer. The government also announced a new Life Sciences Large Investment Portfolio, designed to streamline applications for companies ready to invest over £250 million. This “Trusted Trader” status for major investors—initially piloted in Liverpool and Manchester—aims to move the UK from a “System of Record” to a “System of Action” in global health.
The Growth Hub Verdict: Precision as a Strategy
The common thread between the breakthroughs at MACH 2026 and this £80m Life Sciences boost is Precision and Velocity. Whether it is Fives Landis collapsing a 16-hour grinding process or Birmingham University speeding up the “tumour-to-vaccine” journey, the UK’s growth is being driven by the ability to out-think the competition.
📍 Looking to scale?
If your firm operates in the medical supply chain or precision engineering, the opportunities within the Life Sciences Sector Plan are immense. Visit the Manufacturing Revenue Growth Summit Team at Stand 18-411 this week to discuss how to align your technical capabilities with these massive national investment streams.
